Further evidence for the role of MET in autism susceptibility. Thanseem I, Nakamura K, Miyachi T, Toyota T, Yamada S, Tsujii M, Tsuchiya KJ, Anitha A, Iwayama Y, Yamada K, Hattori E, Matsuzaki H, Matsumoto K, Iwata Y, Suzuki K, Suda S, Kawai M, Sugihara G, Takebayashi K, Takei N, Ichikawa H, Sugiyama T, Yoshikawa T, Mori N.Neurosci Res. 2010 Oct;68(2):137-41. Epub 2010 Jul 6.
Detection of endogenous MET in HepG2 cell line. 10 ug/lane of HepG2 cell lysate was used to examine the expression of human MET. Lanes 1-5 represent MET monoclonal antibody, clone 6AT1785 (Cat # MAB1145). Lane 6 represents auto-phosohorylated-MET in HepG2 cell line detected by anti-phospho-MET monoclonal antibody (Cat # MAB0115).
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq